Though unlikely with typical product concentrations that fall within safe parameters, awareness of this risk remains important
Residual disability, estimated to affect 6% of neurologic patients, is the most feared outcome of cobalamin deficiency and is likely to persist if still present after 6 to 12 months of treatment
It accomplishes this through several distinct mechanisms: Collagen and elastin stimulation: GHK-Cu upregulates the genes responsible for collagen I, collagen III, and elastin synthesis the structural proteins that give skin its firmness, bounce, and thickness
They have lots of different effects and we are in the early stages of exploring peptide therapeutics
GHK-Cu stimulates fibroblasts to produce collagen, elastin, and glycosaminoglycans the structural proteins that keep skin firm and tissue elastic